Alnylam shelves anemia project but prioritises new programs
This article was originally published in Scrip
Executive Summary
Alnylam Pharmaceuticals has decided to suspend further development of ALN-HPN, the investigative treatment for refractory anemia for which it had been hoping to find a partner.